Primer composition, detection method and detection device for simultaneously detecting pathogenic bacteria genes and drug-resistant genes
By providing primer compositions and loop-mediated isothermal amplification methods for detecting sepsis pathogens and drug-resistant genes, the problems of long diagnosis time, high cost and insufficient sensitivity in the prior art are solved, and rapid , accurate test results are suitable for the prevention and diagnosis and treatment of critical illnesses in elderly disabled people.
Patent Information
- Application Number
- CN202411088549.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-08
- Publication Date
- 2024-11-15
AI Technical Summary
The prior art is difficult to quickly, accurately and at low cost to detect pathogenic bacteria and drug-resistant genes in sepsis patients, resulting in long diagnosis time, high cost, insufficient sensitivity, and delayed antibiotic treatment under mixed infection of multiple pathogens, resulting in a decrease in patient survival rate.
A primer composition for simultaneously detecting the pathogenic genes and drug-resistant genes of Acinetobacter baumannii and Enterococcus faecalis are provided. The detection results can be obtained within 40 minutes using a loop-mediated isothermal amplification method and combined with a detection device.
It realizes convenient, fast and accurate detection, has high sensitivity and resistance, and is suitable for the prevention and diagnosis of critical illnesses of elderly disabled people, reducing the time and cost of sepsis diagnosis.
Smart Images

Figure CN118957111A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of bacteria detection, and in particular relates to a primer composition, a detection method and a detection device for simultaneously detecting pathogen genes and drug-resistant genes. Background Art
[0002] The number of elderly patients with sepsis increases year by year, with a mortality rate of over 30%. Currently, antimicrobial drugs are mostly used in clinical treatment of elderly sepsis, so early diagnosis and treatment are particularly important for guiding medication for elderly patients with sepsis. Sepsis is a syndrome that races against time, with severe mixed infections. Anti-infection treatment is the core measure for sepsis treatment. Therefore, rapid and accurate clinical point-of-care (POCT) technology is crucial for diagnosing and detecting pathogens in sputum, urine, and blood of elderly disabled people.
[0003] At present, the pathogens that cause sepsis mainly include Acinetobacter baumannii and Enterococcus faecalis. Acinetobacter baumannii is a member of the Moraxellaceae family of the genus Acinetobacter of the class Proteobacteria. It is an important Gram-negative aerobic bacillus in clinical practice. Due to its high adaptability, invasiveness, motility, and ability to colonize and survive in the hospital environment, its main characteristics are its strong survival ability in the environment, which seriously restricts the efficacy of antimicrobial drugs. In 2017, the WHO announced that carbapenem-resistant Acinetobacter baumannii topped the list of urgently needed drug-resistant bacteria. This strain can be found in various environments, including soil, water, and food, and is often isolated from medical equipment. Because it settles and lives on many medical devices, it can cause serious infections in immunocompromised people and is one of the common pathogens in sepsis infections.
[0004] Enterococcus faecalis, Enterococcus family, Enterococcus genus, is a facultative anaerobic Gram-positive lactic acid bacteria. The body of Enterococcus faecalis is spherical or chain-shaped, with a diameter of about 1.5 mm, no capsule, no spores, strong adaptability and resistance to the environment, can tolerate a variety of antibiotics such as carbapenem antibiotics and tetracyclines, and has no strict requirements for growth conditions.
[0005] Clinically, sepsis pathogen diagnosis is routinely performed using isolation culture, smear microscopy, serological testing, PCR, RT-PCR or next-generation sequencing, which are time-consuming, poorly resistant to inhibition, and expensive, and the detection sensitivity needs to be improved. Therefore, there is an urgent need to provide a rapid, efficient, low-cost, highly sensitive, and highly resistant to inhibition sepsis diagnostic technology.
[0006] In addition, sepsis has an acute course and is often accompanied by mixed infections with multiple pathogens. Patients should be treated with broad-spectrum antibiotics as soon as possible. For every hour of delay in antibiotic treatment, the patient's survival rate decreases by an average of 7.6%; if antibiotic treatment is not given within 24 hours, the survival rate will drop sharply from 80% to 10%. In clinical treatment, carbapenems and tetracyclines are key drugs for dealing with bacterial infections caused by sepsis. However, with the widespread use of antibiotics, strains resistant to these two types of antibiotics continue to emerge, becoming a major obstacle to the clinical treatment of sepsis. Therefore, while detecting sepsis pathogens, identifying the resistance of pathogenic strains at the same time will effectively promote the effectiveness of clinical treatment. Summary of the invention
[0007] In order to solve the above technical problems, the present invention provides a primer combination, a detection method and a detection device for simultaneously detecting pathogen genes and drug-resistant genes. The primer combination provided by the present invention can simultaneously detect two pathogen genes and two drug-resistant genes that cause sepsis, and can detect the results conveniently, quickly and accurately; the detection method has a better effect and can obtain the test results within 40 minutes.
[0008] To achieve the above object, the present invention provides the following solutions:
[0009] The present invention provides a primer composition for simultaneously detecting pathogen genes and drug-resistant genes, wherein the pathogen genes are Acinetobacter baumannii cloR pathogenic gene and Enterococcus faecalis nylA pathogenic gene, and the drug-resistant genes are carbapenem antibiotic resistance gene KPC2 and tetracycline antibiotic resistance gene tet (X4). The primer composition comprises nucleotide sequences shown in SEQ ID No. 1-20.
[0010] Furthermore, the nucleotide sequence of the primer combination used to detect the Acinetobacter baumannii cloR pathogenic gene is shown in SEQ ID No. 1-5.
[0011] Furthermore, the nucleotide sequence of the primer composition for detecting the nylA pathogenic gene of Enterococcus faecalis is shown in SEQ ID No.6-10.
[0012] Furthermore, the nucleotide sequence of the primer composition for detecting the carbapenem antibiotic resistance gene KPC2 is shown in SEQ ID No.11-16.
[0013] Furthermore, the nucleotide sequence of the primer composition for detecting the tetracycline antibiotic resistance gene tet (X4) is shown in SEQ ID No. 17-20.
[0014] Furthermore, the primer composition also includes a DNA molecule having the same function as the described nucleotide sequence after one or more nucleotides are substituted and / or deleted and / or added to the nucleotide sequence shown in SEQ ID No. 1-20.
[0015] The present invention also provides a method for simultaneously detecting pathogen genes and drug-resistant genes, the method comprising the step of using the primer combination to perform detection through a loop-mediated isothermal amplification method.
[0016] Furthermore, the reaction conditions of the loop-mediated isothermal amplification method are a constant temperature of 60-65°C for 40 minutes, the molar concentration ratio of the primer composition SEQ ID No.1-5 for detecting the cloR pathogenic gene of Acinetobacter baumannii is 1:1:4-16:4-16:2-8; the molar concentration ratio of the primer composition SEQ ID No.6-10 for detecting the nylA pathogenic gene of Enterococcus faecalis is 1:1:4-16:4-16:2-8; the molar concentration ratio of the primer composition SEQID No.11-16 for detecting the carbapenem antibiotic resistance gene KPC2 is 1:1:4-16:4-16:2-8:2-8; the molar concentration ratio of the primer composition for detecting the tetracycline antibiotic resistance gene tet (X4) is 1:1:4-16:4-16.
[0017] The present invention also provides a detection device for detecting pathogenic genes and drug-resistant genes causing sepsis, wherein the detection device comprises the primer combination, and the detection device comprises a kit and / or a gene chip.
[0018] Furthermore, the detection step of the detection device includes:
[0019] (1) extracting genomic nucleic acid from bacteria or other types of samples to be tested;
[0020] (2) Using the gene extracted in step (1) as a template, the primer combination is used to perform reverse transcription and loop-mediated isothermal amplification on the cloR pathogenic gene of Acinetobacter baumannii, the nylA pathogenic gene of Enterococcus faecalis, the carbapenem antibiotic resistance gene KPC2, and the tetracycline antibiotic resistance gene tet (X4).
[0021] The primer combination of the present invention can be used to detect whether a sample contains pathogens: Acinetobacter baumannii, Enterococcus faecalis, and whether the pathogens contain drug-resistant genes: carbapenem-resistant KPC2 gene, tetracycline-resistant tet (X4) gene.
[0022] If the above primer combination can be used to specifically amplify the gene cDNA template in the sample, then the sample to be tested contains or is suspected of containing the pathogenic genes of Acinetobacter baumannii and Enterococcus faecalis, and the carbapenem antibiotics resistance KPC2 gene, and the tetracycline antibiotics resistance tet (X4) gene; if the gene cDNA template in the sample cannot be specifically amplified, then the sample to be tested does not contain the pathogenic genes of Acinetobacter baumannii and Enterococcus faecalis, and the carbapenem antibiotics resistance KPC2 gene, and the tetracycline antibiotics resistance tet (X4) gene.
[0023] The present invention discloses the following technical effects:
[0024] The primer composition provided by the present invention is used for detecting pathogenic genes and drug-resistant genes of common pathogens causing sepsis, which can simultaneously detect pathogenic genes of Acinetobacter baumannii and Enterococcus faecalis and the carbapenem-resistant KPC2 gene and the tetracycline-resistant tet (X4) gene, and can detect the results conveniently, quickly and accurately. The method has strong specificity and high sensitivity, and the detection results can be obtained within 40 minutes.
[0025] In the detection method provided by the present invention, the loop-mediated isothermal amplification technology (LAMP) adopted has the characteristics of rapidity, high efficiency, low cost, high sensitivity, strong resistance to inhibition, etc. It is the core link for the prevention, diagnosis and treatment of critical and severe diseases, medication guidance, and prognosis and elderly care for the elderly and disabled, and is a key technology for the diagnosis of sepsis. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0027] Figure 1 The fluorescence curve graph of Acinetobacter baumannii, Enterococcus faecalis, tetracycline antibiotic resistance genes, carbapenem antibiotic resistance genes, human genome and blank control amplified by Acinetobacter baumannii primers in Example 1 of the present invention;
[0028] Figure 2 The fluorescence curve graph of the Enterococcus faecalis primers amplifying Acinetobacter baumannii, Enterococcus faecalis, tetracycline antibiotic resistance genes, carbapenem antibiotic resistance genes, human genome and blank control in Example 2 of the present invention;
[0029] Figure 3The fluorescence curve graph of the tetracycline antibiotic resistance gene primers amplifying Acinetobacter baumannii, Enterococcus faecalis, tetracycline antibiotic resistance genes, carbapenem antibiotic resistance genes, human genome and blank control in Example 3 of the present invention;
[0030] Figure 4 The fluorescence curve graph of the amplification of Acinetobacter baumannii, Enterococcus faecalis, tetracycline antibiotic resistance genes, carbapenem antibiotic resistance genes, human genome and blank control by the carbapenem antibiotic resistance gene primers in Example 4 of the present invention;
[0031] Figure 5 The primer amplification 10 of Acinetobacter baumannii in Example 1 of the present invention 4 copies / μL Acinetobacter baumannii, 10 3 copies / μL Acinetobacter baumannii, 10 2 copies / μL Fluorescence curves of Acinetobacter baumannii, human genome, and blank control;
[0032] Figure 6 The primer amplification 10 of Enterococcus faecalis in Example 2 of the present invention 4 copies / μL Enterococcus faecalis, 10 3 copies / μL Enterococcus faecalis, 10 2 copies / μL Fluorescence curves of Enterococcus faecalis, human genome and blank control;
[0033] Figure 7 The tetracycline antibiotic resistance gene primer amplification 10 in Example 3 of the present invention 4 copies / μL tetracycline antibiotic resistance genes, 10 3 copies / μL tetracycline antibiotic resistance genes, 10 2 copies / μL Fluorescence curves of tetracycline antibiotic resistance genes, human genome and blank control;
[0034] Figure 8 The primers for amplifying the carbapenem antibiotic resistance gene in Example 4 of the present invention are 10 4 copies / μL carbapenem antibiotic resistance genes, 10 3 copies / μL carbapenem antibiotic resistance genes, 10 2 copies / μL Fluorescence curves of carbapenem antibiotic resistance genes, human genome and blank control. DETAILED DESCRIPTION
[0035] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0036] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.
[0037] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.
[0038] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.
[0039] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.
[0040] The test methods used in the following implementations, unless otherwise specified, are all commonly used experimental methods in this field;
[0041] Unless otherwise specified, the experimental materials used in the following examples are all commonly used experimental materials in this field.
[0042] The primer composition of the present invention for simultaneously detecting the cloR pathogenic gene of Acinetobacter baumannii, the nylA pathogenic gene of Enterococcus faecalis, the carbapenem antibiotic resistance gene KPC2 and the tetracycline antibiotic resistance gene tet (X4) resistance gene comprises the nucleotide sequences shown in SEQ ID No. 1-20.
[0043] The method for detecting using the above primer combination is as follows:
[0044] (1) extracting genomic nucleic acid from bacteria or other types of samples to be tested;
[0045] (2) Using the genomic nucleic acid extracted in step (1) as a template, the above primer combination is used to reverse transcribe and loop-mediated isothermal amplify the cloR pathogenic gene of Acinetobacter baumannii, the nylA pathogenic gene of Enterococcus faecalis, the carbapenem antibiotic resistance gene KPC2, and the tetracycline antibiotic resistance gene tet (X4).
[0046] Example 1
[0047] This embodiment is used to detect the cloR pathogenic gene of Acinetobacter baumannii, and the specific method includes:
[0048] The plasmid containing the cloR pathogenic gene of Acinetobacter baumannii was synthesized by Beijing Qingke Biotechnology Co., Ltd. and used in the detection kit to detect Acinetobacter baumannii. The synthesized plasmid was used as a template, and the reaction system was shown in Table 1. The configured reaction system was set up in accordance with Table 2 on the fluorescence quantitative PCR instrument to detect the fluorescence excitation light of 480-500nm.
[0049] Table 1 Acinetobacter baumannii fluorescence quantitative PCR reaction tube 10 μL reaction system
[0050]
[0051] Table 2 LAMP reaction procedure
[0052] TTTCC
[0053] BIP (SEQ ID No. 4): CGGGTGTTCCTGTAGGCAACCGGTTTTTACCCAGAGCAG
[0054] LB(SEQ ID No. 5):AGTGCGCAGACGTCCAT.
[0055] The results after the reaction are as follows Figure 1 and Figure 5 As shown. Figure 1 It can be seen that the fluorescence curve of the plasmid of Acinetobacter baumannii is a specific S-shaped curve; the fluorescence curves of Enterococcus faecalis, tetracycline antibiotic resistance genes, carbapenem antibiotic resistance genes, human genome and blank control are the baselines. It can be seen that the above primer combination can specifically detect Acinetobacter baumannii. Figure 5 It can be seen that 10 4 copies / μL Acinetobacter baumannii plasmid, 10 3 copies / μL Acinetobacter baumannii plasmid, 10 2copies / μL of Acinetobacter baumannii plasmid showed a specific S-type fluorescence curve within 40 min. 2 At a template concentration of 10 copies / μL, the detection of Acinetobacter baumannii was completed within 40 minutes, with high sensitivity.
[0056] Example 2
[0057] This embodiment is used to detect the nylA pathogenic gene of Enterococcus faecalis, and the specific method includes:
[0058] A plasmid containing the nylA pathogenic gene of Enterococcus faecalis was synthesized by Beijing Qingke Biotechnology Co., Ltd. and used in the detection kit to detect Enterococcus faecalis. The synthesized plasmid was used as a template, the reaction system was the same as in Example 1, and the reaction procedure was the same as in Example 1; the nucleotide sequences of the primers for Enterococcus faecalis are as follows:
[0059] F3 (SEQ ID No. 6): GGAGCTGCTATTGATTTCG
[0060] B3(SEQ ID No.7):GTGAGTGGATCGGTGAAT
[0061] FIP(SEQ ID No.8):CGGAATGGATACTTCTCATCCCAGCTTGACAGTTTCTATGAGAGA
[0062] BIP(SEQ ID No.9):GTGCGCCATATCAAGTATCGCACACAAAAAGCTATCTTCAACC
[0063] LB (SEQ ID No. 10): CAGTTTGAGTGGCAAACACATCCAA.
[0064] The results after the reaction are as follows Figure 2 and Figure 6 As shown. Figure 2 It can be seen that the fluorescence curve of the Enterococcus faecalis plasmid is a specific S-shaped curve; the fluorescence curves of Acinetobacter baumannii, tetracycline antibiotic resistance genes, carbapenem antibiotic resistance genes, human genomic cDNA and blank control are the baselines. It can be seen that the above primer combination can specifically detect Enterococcus faecalis. Figure 6 It can be seen that 10 4 copies / μL Enterococcus faecalis plasmid, 10 3 copies / μL Enterococcus faecalis plasmid, 10 2 copies / μL Enterococcus faecalis plasmid showed a specific S-type fluorescence curve within 40 min.2 At a template concentration of 100 copies / μL, the detection of Enterococcus faecalis was completed within 40 minutes, with high sensitivity.
[0065] Example 3
[0066] This embodiment is used to detect the carbapenem antibiotic resistance gene KPC2, and the specific method includes:
[0067] A plasmid containing the carbapenem antibiotic resistance gene KPC2 was synthesized by Beijing Qingke Biotechnology Co., Ltd. and used in a test kit to detect carbapenem antibiotic resistance. The synthesized plasmid was used as a template, the reaction system was the same as in Example 1, and the reaction procedure was the same as in Example 1; the nucleotide sequences of the primers for the carbapenem antibiotic resistance gene are as follows:
[0068] F3 (SEQ ID No. 11): TGGCTTTTCTGCCACCG
[0069] B3 (SEQ ID No. 12): TGCGAGCCAGCACAGC
[0070] FIP(SEQ ID No.13):TACACACCGATGGAGCCGCCCCTCGTCGCGGAACCAT
[0071] BIP(SEQ ID No.14):GGCTCAGGCGCAACTGTAAGTGCAGCAAGAAAGCCCTTG AA
[0072] LF(SEQ ID No.15):AGTCCTGTTCGAGTTTAGCGA
[0073] LB (SEQ ID No. 16):CTGAGGAGCGCTTCCCACT.
[0074] The results after the reaction are as follows Figure 3 and Figure 7 As shown. Figure 3 It can be seen that the fluorescence curve of the carbapenem antibiotic resistance gene plasmid is a specific S-shaped curve; the fluorescence curves of Acinetobacter baumannii, Enterococcus faecalis, tetracycline antibiotic resistance genes, human genomic cDNA and blank control are the baselines. It can be seen that the above primer combination can specifically detect carbapenem antibiotic resistance. Figure 7 It can be seen that 10 4 copies / μL carbapenem antibiotic resistance gene plasmid, 10 3 copies / μL carbapenem antibiotic resistance gene plasmid, 10 2All the plasmids containing carbapenem antibiotic resistance genes showed a specific S-type fluorescence curve within 40 min. 2 At a template concentration of 20 copies / μL, the detection of carbapenem antibiotic resistance genes was completed within 40 minutes, with high sensitivity.
[0075] Example 4
[0076] This embodiment is used to detect tetracycline antibiotic resistance gene tet (X4), and the specific method includes:
[0077] A plasmid containing the tetracycline antibiotic resistance gene tet (X4) was synthesized by Beijing Qingke Biotechnology Co., Ltd. and used in a detection kit to detect tetracycline antibiotic resistance. The synthesized plasmid was used as a template, the reaction system was the same as in Example 1, and the reaction procedure was the same as in Example 1; the nucleotide sequences of the primers of the tetracycline antibiotic resistance gene are as follows:
[0078] F3(SEQ ID No.17):GCCAATGGTGGAATGTCT
[0079] B3 (SEQ ID No. 18): ACTTATTCCAAAATGCAATGC
[0080] FIP (SEQ ID No.19):TCTGGATGATGAATATCGGCTTGTA-AAAATTTGTTACCGAC ACGGA
[0081] BIP (SEQ ID No. 20): TGGATTTTTTCAGCTATGCAATGGA-ACCATTATTATTAGGAT TCGCAA.
[0082] The results after the reaction are as follows Figure 4 and Figure 8 As shown. Figure 4 It can be seen that the results obtained after the reaction are as follows Figure 4 As shown by Figure 4 It can be seen that the fluorescence curve of tetracycline antibiotic resistance gene plasmid is a specific S-shaped curve; the fluorescence curves of Acinetobacter baumannii, Enterococcus faecalis, carbapenem antibiotic resistance gene, human genomic cDNA and blank control are the baselines. It can be seen that the above primer combination can specifically detect tetracycline antibiotic resistance. Figure 8 It can be seen that 10 4 copies / μL tetracycline antibiotic resistance gene plasmid, 10 3 copies / μL tetracycline antibiotic resistance gene plasmid, 10 2All the tetracycline antibiotic resistance gene plasmids showed a specific S-type fluorescence curve within 40 minutes. 2 The tetracycline antibiotic resistance genes were detected within 40 min at a template concentration of 100 copi es / μL, with high sensitivity.
[0083] The primer combination prepared in Examples 1-4 is used to diagnose sepsis using a loop-mediated isothermal amplification (LAMP) method, wherein the molar concentration ratio of the primer combination F3, B3, FIP, BIP and LB in Example 1 is 1:1:4-16:4-16:2-8; wherein the molar concentration ratio of the primer combination F3, B3, FIP, BIP and LB in Example 2 is 1:1:4-16:4-16:2-8; wherein the molar concentration ratio of the primer combination F3, B3, FIP, BIP, LF and LB in Example 3 is 1:1:4-16:4-16:2-8:2-8; wherein the molar concentration ratio of the primer combination F3, B3, FIP, BIP in Example 4 is 1:1:4-16:4-16; the reaction conditions of the loop-mediated isothermal amplification are constant temperature detection for 40 min at 60-65°C. It was finally found that the primer combination in this method can specifically detect the gene fragments of the corresponding pathogen, with high sensitivity and specificity in the detection of human genome and other pathogens. The results can be read within 40 minutes and the experiment can be repeated.
[0084] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.
Claims
1. A primer combination for simultaneously detecting pathogen genes and drug resistance genes, characterized in that: The pathogenic bacteria genes include the cloR pathogenic gene of Acinetobacter baumannii and the nylA pathogenic gene of Enterococcus faecalis, the drug resistance genes include the carbapenem antibiotic resistance gene KPC2 and the tetracycline antibiotic resistance gene tet (X4), and the primer composition includes the nucleotide sequences shown in SEQ ID No. 1-20.
2. The primer composition for simultaneously detecting pathogen genes and drug-resistant genes according to claim 1, characterized in that: The nucleotide sequences of the primer combination used to detect the Acinetobacter baumannii cloR pathogenic gene are shown in SEQ ID No. 1-5.
3. The primer composition for simultaneously detecting pathogen genes and drug-resistant genes according to claim 1, characterized in that: The nucleotide sequences of the primer compositions for detecting the nylA pathogenic gene of Enterococcus faecalis are shown in SEQ ID No. 6-10.
4. The primer composition for simultaneously detecting pathogen genes and drug-resistant genes according to claim 1, characterized in that: The nucleotide sequences of the primer composition used to detect the carbapenem antibiotic resistance gene KPC2 are shown in SEQ ID No. 11-16.
5. The primer composition for simultaneously detecting pathogen genes and drug-resistant genes according to claim 1, characterized in that: The nucleotide sequences of the primer composition used to detect the tetracycline antibiotic resistance gene tet (X4) are shown in SEQ ID No. 17-20.
6. The primer composition for simultaneously detecting pathogen genes and drug-resistant genes according to claim 1, characterized in that: The primer composition also includes a DNA molecule having the same function as the described nucleotide sequence after one or more nucleotides are substituted and / or deleted and / or added to the nucleotide sequence shown in SEQ ID No. 1-20.
7. A method for simultaneously detecting pathogen genes and drug resistance genes, characterized in that: The method comprises the step of detecting by a loop-mediated isothermal amplification method using the primer composition according to any one of claims 1 to 6.
8. The method for detecting common pathogenic bacteria causing sepsis according to claim 7, characterized in that: The reaction conditions of the loop-mediated isothermal amplification method are a constant temperature of 60-65°C for 40 minutes, the molar concentration ratio of the primer composition SEQ ID No.1-5 for detecting the cloR pathogenic gene of Acinetobacter baumannii is 1:1:4-16:4-16:2-8; the molar concentration ratio of the primer composition SEQ ID No.6-10 for detecting the nylA pathogenic gene of Enterococcus faecalis is 1:1:4-16:4-16:2-8; the molar concentration ratio of the primer composition SEQ ID No.11-16 for detecting the carbapenem antibiotic resistance gene KPC2 is 1:1:4-16:4-16:2-8:2-8; the molar concentration ratio of the primer composition for detecting the tetracycline antibiotic resistance gene tet (X4) is 1:1:4-16:4-16.
9. A detection device for detecting pathogenic genes and drug-resistant genes causing sepsis, characterized in that: The detection device comprises the primer combination according to any one of claims 1 to 6, and the detection device comprises a kit and / or a gene chip.
10. The detection device according to claim 9, characterized in that: The detection step of the detection device comprises: (1) extracting genomic nucleic acid from bacteria or other types of samples to be tested; (2) Using the genomic nucleic acid extracted in step (1) as a template, the primer combination described in any one of claims 1 to 6 is used to perform reverse transcription and loop-mediated isothermal amplification on the cloR pathogenic gene of Acinetobacter baumannii, the nylA pathogenic gene of Enterococcus faecalis, the carbapenem antibiotic resistance gene KPC2, and the tetracycline antibiotic resistance gene tet (X4).
